Bisphosphonates and teriparatide for the prevention of osteoporotic fractures in postmenopausal women.
Contributors: Morphet, Suzanne.; Canadian Coordinating Office for Health Technology Assessment.; Canadian Agency for Drugs and Technologies in Health.
Series: Technology overview -- no. 23; Technology overview (Ottawa, Ont.) -- issue 23.
Publisher: Canadian Coordinating Office for Health Technology Assessment
Published: 2006
Place of publication: Ottawa
Language: eng
Number of pages: 11
Subjects: Osteoporosis -- Prevention.; Osteoporosis -- Treatment.; Osteoporosis in women -- Prevention.; Osteoporosis in women -- Teatment.; Diphosphonates -- Therapeutic use.
Notes: "October 2006..

Suzanne Morphet assisted in creating this overview.

"This overview is based on two technology reports commissioned by CADTH: Wells GA, Cranney A, Boucher M, Peterson J, Shea B, Robinson V, Coyle D, Tugwell P. Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no. 68]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006; and Coyle D, Tahar AH, Murphy G, Peras C, Skidmore B, Boucher M, Husereau D. Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and economic analysis [Technology report no. 69]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006."

At head of title: Canadian Agency for Drugs and Technologies in Health.

Includes bibliographical references (p. 10-11).